De-Risking RNAi Therapeutic Development for Hereditary Angioedema Through CytoSolve® Systems Modeling in Collaboration with Alnylam

Alnylam is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. The company focuses on developing transformative siRNA-based medicines for serious and rare diseases, including hereditary angioedema (HAE), by selectively silencing disease-causing genes.

Challenge

Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder characterized by recurrent, non-itchy swelling of subcutaneous and submucosal tissues. The disease arises from functional defects in C1 esterase inhibitor (C1INH) or factor XII, resulting in excessive bradykinin production and increased vascular permeability. While siRNA therapeutics offer a powerful approach to targeting genes in the contact activation pathway, clinical translation is challenged by limited understanding of how knockdown of individual genes propagates through the interconnected biomolecular network. The lack of a systems-level correlation between pathway components constrained target selection, dose optimization, and combination siRNA strategies.

How CytoSolve Helped

CytoSolve collaborated with Alnylam to transform the molecular pathways governing contact activation and bradykinin production into validated, mechanistic in silico models. CytoSolve:

  • Converted complex biochemical interactions within the contact activation cascade into quantitative computational architectures.
  • Modeled relationships between siRNA-mediated target knockdown and downstream bradykinin production.
  • Performed differential sensitivity analyses to evaluate how perturbations of specific genes influence vascular permeability drivers.
  • Validated simulation outputs against published in vivo and in vitro experimental data.
  • Successfully predicted outcomes from Alnylam’s internal in vivo studies, confirming model fidelity and translational relevance.

Key Benefits Realized

  • Mechanistic Clarity Across the Contact Activation Pathway
    Established a systems-level understanding of how molecular perturbations propagate to bradykinin-driven edema.
  • Predictive Target–Response Modeling
    Enabled quantitative prediction of therapeutic response to siRNA knockdown of relevant HAE genes.
  • Reduced Experimental Risk and Cost
    Leveraged validated simulations to prioritize targets and strategies before costly in vivo experimentation.
  • Foundation for Combination siRNA Strategies
    Provided a computational framework to systematically explore multi-target siRNA combinations beyond single-gene approaches.
  • Translational Confidence
    Demonstrated alignment between in silico predictions and experimental outcomes, strengthening decision-making in drug development.

Outcome

Through its collaboration with CytoSolve®, Alnylam established a validated computational systems model of hereditary angioedema biology, linking siRNA target knockdown to clinically relevant bradykinin responses. This commercialization-ready platform de-risked RNAi development, enabled rational exploration of combination siRNA therapies, and created a scalable initiative for future pipeline expansion. The case highlights how CytoSolve® empowers pharmaceutical innovators to translate complex pathway biology into predictive, decision-driving assets that accelerate development of life-saving therapeutics.